Related by context. All words. (Click for frequent words.) 78 distant metastases 75 tumor recurrence 75 lymph node metastases 74 lymph node metastasis 73 locoregional recurrence 73 biochemical recurrence 72 lymph node involvement 72 advanced adenoma 71 breast carcinoma 71 locoregional 71 pT3 70 histological subtype 70 metastases 70 pCR 70 nodal metastases 70 advanced adenomas 70 nodal metastasis 70 neoadjuvant therapy 70 metastatic disease 70 prostate cancer CaP 69 liver metastasis 69 nonmetastatic 69 histologic subtype 69 pancreatic adenocarcinoma 69 HNSCC 69 node metastases 69 colorectal carcinoma 69 epithelial tumors 69 PCa 69 PSADT 69 histologic 69 metachronous 68 neoplasm 68 biochemical relapse 68 SUVmax 68 micrometastases 68 CIN2 + 68 urothelial carcinoma 68 T1c 68 esophageal carcinoma 68 invasive ductal 68 HER2 overexpression 68 ipsilateral breast 68 serous ovarian cancer 68 pT2 68 underwent surgical resection 67 NMIBC 67 liver metastases 67 hepatocellular carcinomas 67 malignant neoplasm 67 precursor lesions 67 colorectal adenoma 67 neoadjuvant chemotherapy 67 operable breast cancer 67 metastatic cancer 67 K ras mutations 67 lobular carcinoma 67 bone metastasis 67 mucinous 67 sarcomatoid 67 lymphocytosis 67 hepatocellular carcinoma 67 metastatic 67 micrometastasis 67 renal cell carcinomas 67 thyroid carcinoma 67 invasive carcinomas 67 chemoradiotherapy 67 ductal carcinomas 66 KRAS mutations 66 rebleeding 66 metastasis 66 malignant lesions 66 adenocarcinomas 66 univariate analysis 66 papillary renal cell carcinoma 66 gastric adenocarcinoma 66 lymphadenectomy 66 cervical carcinoma 66 lymphovascular invasion 66 Kaplan Meier analysis 66 SLNB 66 prognostic factor 66 specific antigen PSA 66 stage IIIA 66 endometrial carcinoma 66 recurrent NSCLC 66 GSTP1 66 multivariable analysis 66 renal carcinoma 66 clinicopathological features 66 breast carcinomas 66 axillary lymph nodes 65 gastric carcinoma 65 HGPIN 65 neoplasms 65 FDG PET 65 HBeAg negative 65 adenoma 65 progesterone receptor negative 65 thymoma 65 adenomatous polyps 65 adjuvant radiotherapy 65 GISTs 65 carcinomas 65 metastatic GIST 65 neoadjuvant 65 F FDG PET 65 nonfatal MI 65 carcinoid tumors 65 histologically confirmed 65 preoperative chemotherapy 65 carcinoid 65 tumoral 65 HER2 expression 65 advanced neoplasia 65 immunohistochemical staining 65 prostate carcinoma 65 metastatic prostate cancer 65 HER2 negative 65 pancreatic lung 65 epithelial ovarian cancer 65 endometrial cancers 65 underwent resection 65 ovarian carcinoma 65 PSA nadir 65 prostate cancer PCa 65 MLH1 65 thyroglobulin 65 CIN3 65 basal cell carcinoma BCC 65 Hurthle cell 65 bladder cancers 65 HER2 positive cancers 65 prostate adenocarcinoma 65 hepatocellular carcinoma HCC 65 axillary lymph node 65 unresectable 65 MGUS 65 situ LCIS 65 endometrial hyperplasia 65 cancer mCRC 65 TIMP 64 Papillary 64 stage IIIb IV 64 intestinal metaplasia 64 curative resection 64 recurrent glioblastoma multiforme 64 HER2 positive metastatic breast 64 rs# [002] 64 extracapsular extension 64 Folfox 64 response pCR 64 EGFR mutation positive 64 HER2 amplification 64 EUS FNA 64 axillary node 64 postoperative complication 64 cisplatin resistant 64 BRCA2 mutation carriers 64 peritoneal cancer 64 premalignant 64 Immunohistochemical staining 64 carcinoids 64 fallopian tube carcinoma 64 contralateral breast 64 lobular carcinomas 64 % CI #.#-#.# [003] 64 seminal vesicle invasion 64 tumor histology 64 prognostic variables 64 papillary 64 metastatic lesions 64 TIMP 1 64 carcinoma 64 Kaplan Meier 64 genotypic resistance 64 tumors GIST 64 neoplasias 64 TEAEs 64 EGFR mutations 64 clinically localized prostate 64 hepatic cirrhosis 64 Metastatic 64 resected pancreatic cancer 64 completely resected 64 atypical hyperplasia 64 tumor shrinkage 64 pulmonary metastases 64 seminoma 64 squamous histology 64 Kaplan Meier estimates 64 gefitinib Iressa 64 T1a 64 stage IIIB 64 adjuvant therapies 64 patients evaluable 64 prognostic significance 64 mesotheliomas 64 mRNA expression 64 hypermethylated 64 differentiated thyroid 64 non squamous NSCLC 64 % CI #.#-#.# [007] 64 pancreatic carcinoma 64 postoperative chemotherapy 64 metastatic gastric 64 lung metastases 64 neoplasia 64 malignancies 64 lobular cancer 64 advanced hepatocellular carcinoma 63 xenograft models 63 unresectable tumors 63 pheochromocytoma 63 Median progression 63 intracranial hemorrhage ICH 63 invasive carcinoma 63 ERBB2 63 estrogen receptor ER 63 neoplastic 63 multivariate Cox 63 nasopharyngeal carcinoma 63 Squamous 63 #.#ng/ml 63 ductal adenocarcinoma 63 CaP 63 confidence interval #.#-#.# 63 mRCC 63 proximal colon 63 skeletal metastases 63 BRAF mutations 63 severe neutropenia 63 metastatic pancreatic 63 lung metastasis 63 resectable 63 mutated KRAS 63 metastatic renal cell carcinoma 63 obstructive coronary artery 63 pathologic diagnosis 63 reinfarction 63 Lymph node 63 Radical prostatectomy 63 leukemia AML 63 ABCB1 63 seminomas 63 hepatic metastases 63 ductal breast cancer 63 metastatic malignant 63 colorectal neoplasms 63 thrombocytopenic 63 radical prostatectomy RP 63 tumor regressions 63 tumor necrosis 63 RRM1 63 squamous 63 cytologic 63 debulking surgery 63 carcinoid tumor 63 MALT lymphoma 63 metastatic bladder 63 prognostic biomarker 63 liver transplant recipients 63 malignant pleural mesothelioma 63 monoclonal gammopathy 63 KRAS mutations occur 63 median survivals 63 HBeAg 63 ipsilateral stroke 63 gastric cancers 63 baseline LDH 63 colorectal adenomas 63 axillary dissection 63 nonmelanoma skin cancers 63 colorectal adenocarcinoma 63 recurrent metastatic 63 squamous cell carcinoma SCC 63 de ath 63 peritoneal carcinomatosis 63 BRCA deficient 63 chemoradiation 63 metastatic RCC 63 gastric cancer 63 uveal melanoma 63 recurrent venous thromboembolism 63 small lymphocytic lymphoma 63 Partial Responses 63 CIN2 63 hormone receptor negative 63 cardiac dysfunction 63 anthracycline taxane 63 axillary nodes 63 cutaneous melanoma 63 papillary thyroid carcinoma 63 progression TTP 63 histologies 63 papillary carcinoma 63 CTEPH 63 prognostic factors 63 myeloproliferative diseases 63 nonfatal myocardial infarction 63 androgen deprivation 63 EGFR mutation 63 definite stent thrombosis 63 smoldering myeloma 63 neutrophil count 63 axillary node dissection 63 metastatic lesion 63 malignancy 63 histologic subtypes 63 ErbB2 positive 63 paragangliomas 62 posttransplant 62 prognostic indicator 62 bronchioloalveolar carcinoma 62 hamartomas 62 Subgroup analysis 62 FDG uptake 62 Clusterin 62 sentinel node 62 malignant neoplasms 62 metastatic malignant melanoma 62 clinicopathological 62 lobular breast cancer 62 gemcitabine carboplatin 62 surgically resected 62 cytogenic 62 brain metastases 62 pelvic lymphadenectomy 62 localized renal 62 RECIST Response Evaluation Criteria 62 hematologic toxicity 62 epithelioid 62 soft tissue sarcomas 62 squamous cell lung cancer 62 wedge resection 62 coronary stenosis 62 pancreatic cancers 62 HSCT 62 FOLFOX4 62 hormone receptor status 62 univariate 62 testicular tumors 62 osteosarcomas 62 ertapenem 62 pituitary adenomas 62 pericardial effusion 62 lung adenocarcinomas 62 Circulating tumor cells 62 5-fluorouracil/leucovorin 62 FDG-PET/CT 62 prospectively defined 62 BRCA mutation carriers 62 radiotherapy RT 62 alanine aminotransferase 62 noncardiac 62 EBRT 62 preoperative PSA 62 tumor progression 62 SSc 62 KRAS wild 62 lung carcinomas 62 GSTM1 62 CTNNB1 62 EGFR mutant 62 invasive lobular 62 colorectal neoplasia 62 imatinib therapy 62 heavily pretreated patients 62 thromboembolic events 62 clinically detectable 62 nonsmall cell lung cancer 62 serum prostate 62 catheter angiography 62 tumor subtypes 62 colorectal cancer CRC 62 haematological toxicity 62 esophageal cancers 62 chromosomal mutations 62 pulmonary metastasis 62 sentinel nodes 62 hepatorenal syndrome 62 p = NS 62 radiochemotherapy 62 hepatocellular cancer 62 NSCLC 62 essential thrombocythemia 62 cholangiocarcinoma 62 CR nPR 62 neoadjuvant treatment 62 IL#B 62 paraganglioma 62 IV NSCLC 62 postoperative mortality 62 lymphocytic 62 endometrial ovarian 62 MACCE 62 atypia 62 histopathologic examination 62 neuroendocrine cancers 62 neurologic complications 62 ADPKD 62 serum PSA 62 polyp recurrence 62 mediastinal 62 relapsed MM 62 KRAS oncogene 62 esophagogastric junction 62 Tumor shrinkage 62 renal tumors 62 prostate colon 62 RASSF1A 62 sentinel lymph node biopsy 62 ERalpha 62 contralateral breast cancer 62 GSTT1 62 oral squamous cell 62 CCyR 62 androgen suppression 62 immunohistochemical analysis 62 recurrent VTE 62 chlorambucil 62 prognostic indicators 62 colorectal tumors 62 progesterone receptor PR 61 lymphadenopathy 61 PITX2 61 elevated ALT 61 adjuvant therapy 61 P = .# 61 CMV disease 61 FLT3 61 immunohistochemical 61 hematological relapse 61 prognostic marker 61 perineural invasion 61 taxane therapy 61 disease progression 61 metastatic carcinoma 61 follicular thyroid cancer 61 medically inoperable 61 endometrioid 61 evaluable patients 61 spontaneous bacterial peritonitis 61 cytogenetic response 61 antigen PSA levels 61 biliary tract cancer 61 histological subtypes 61 sleeve lobectomy 61 Median survival 61 metastatic lung cancer 61 cervical intraepithelial neoplasia 61 mutated K ras 61 nondiabetic patients 61 metastatic tumors 61 adjuvant chemotherapy 61 graft dysfunction 61 mammographic density 61 leukocyte count 61 TYMS 61 prior chemotherapy regimens 61 hematopoietic cancers 61 neuroendocrine tumors 61 histologically proven 61 clinico pathological 61 promoter hypermethylation 61 ductal cancer 61 NNRTI resistance 61 pancreatic prostate 61 esophageal squamous cell carcinoma 61 renal dysfunction 61 median PFS 61 fibrinolysis 61 epithelial ovarian 61 neurologic progression 61 adnexal mass 61 Doxil ® 61 Response Evaluation Criteria 61 bladder ovarian 61 KRAS mutation 61 cerebral infarction 61 iniparib BSI 61 neoplastic lesions 61 CR CRu 61 extramedullary 61 IGFBP 61 hypopharynx 61 cytokeratin 61 undergoing coronary angiography 61 ovarian breast 61 histopathological 61 clinicopathologic 61 multivariate analyzes 61 alkaline phosphatase ALP 61 LHRH receptor positive 61 CC genotype 61 Recurrence Score 61 percutaneous biopsy 61 oral Hycamtin 61 bladder tumors 61 adrenocortical cancer 61 leiomyoma 61 intraoperative complications 61 adenomatous 61 metastatic lymph nodes 61 decompensated cirrhosis 61 immunostaining 61 ischemic lesions 61 CLL SLL 61 gemcitabine chemotherapy 61 histologically 61 BRCA1 mutation carriers 61 hormone receptor positive 61 transgene expression 61 estramustine 61 advanced unresectable 61 hypermethylation 61 atypical ductal hyperplasia 61 chromosomal aberrations 61 leiomyomas 61 idiopathic myelofibrosis 61 Ki# 61 cTnI 61 BCR ABL mutations 61 Hodgkin lymphoma HL 61 CDH1 61 grade cervical intraepithelial 61 bronchogenic carcinoma 61 hypophosphatemia 61 TOP2A 61 endometrial adenocarcinoma 61 HBeAg positive patients 61 metastatic colorectal 61 alanine aminotransferase ALT 61 Prognostic factors 61 ALND 61 lymph node dissection 61 endocrine therapies 61 ductal lobular 61 nodal dissection 61 metastatic cancers 61 acute leukemias 61 rs# [004] 61 HBeAg negative patients 61 p = #.# [003] 61 troponin T 61 Adenomas 61 systolic dysfunction 61 cell adhesion molecule 61 evaluable 61 Adjuvant chemotherapy 61 castrate resistant 61 ERCC1 61 TP# mutations 61 plasma uric acid 61 ABL1 61 cisplatin chemotherapy 61 adenocarcinoma 61 microsatellite instability 61 pegylated liposomal doxorubicin 61 HIV HCV coinfected 61 pheochromocytomas 61 Thal Dex 61 malignant lymphoma 61 lactate dehydrogenase 61 carotid stenosis 61 gastrointestinal stromal tumors GISTs 61 astrocytomas 61 Medullary thyroid cancer 61 histopathologic 61 malignant polyps 61 rectal cancers 61 gastrointestinal cancers 61 complete cytogenetic response 61 parathyroid carcinoma 61 thyroid peroxidase 61 vertebral fracture 61 lymphopenia 61 mediastinal lymph nodes 61 abdominal irradiation 61 tumorigenicity 61 Hazard Ratio 61 HER2 positive 60 undetectable PSA 60 chemoembolization 60 pediatric acute lymphoblastic 60 QTc prolongation 60 adrenalectomy 60 EGFR HER2 60 metastatic neuroendocrine tumors 60 autoimmune thyroid 60 Metastatic breast cancer 60 Recurrence 60 rs# [001] 60 TACE 60 System IPSS 60 preoperative radiotherapy 60 chemotherapy cisplatin 60 B7 H3 60 NSCLC tumors 60 astrocytoma 60 bladder carcinoma 60 neoplastic cells 60 genomic alterations 60 myocardial necrosis 60 glycated hemoglobin levels 60 Leukemias 60 gastroesophageal junction 60 carcinoembryonic antigen 60 macroalbuminuria 60 renal cell carcinoma 60 lymphoproliferative disorders 60 partial remissions 60 octreotide LAR 60 sirolimus stent 60 mg/m2 dose 60 sCJD 60 HF hospitalization 60 cytoreductive surgery 60 radical nephrectomy 60 tumor progression TTP 60 promoter methylation 60 low expressors 60 oropharyngeal cancer 60 urothelial cancer 60 postintervention 60 cervical lymph nodes 60 cytoreduction 60 tumor resection 60 VT VF 60 pancreatic neuroendocrine 60 leukemic cell 60 HBsAg 60 Prostate specific antigen 60 elevated LDH 60 thyroid nodules 60 heavily pretreated 60 ALT normalization 60 APOL1 60 surgically resectable 60 LV dysfunction 60 postoperative morbidity 60 urine cytology 60 elevated transaminases 60 albuminuria 60 recurrent myocardial infarction 60 microvessel density 60 FluCAM arm 60 highest tertile 60 Metastases 60 inducible nitric oxide synthase 60 estrogen receptor negative 60 univariate analyzes 60 thromboembolism 60 rheumatoid factor 60 FOLFIRI 60 anaplastic 60 dacarbazine DTIC 60 intratumoral 60 febrile neutropenia 60 urothelial 60 Febrile neutropenia 60 myeloproliferative neoplasms 60 xenograft tumors 60 serum ALT 60 lung ovary 60 PNET 60 antitumor effect 60 cystectomy 60 precancerous cervical 60 malignant growths 60 SPINK1 60 ovarian lung 60 HBeAg seroconversion 60 cyclin E 60 transurethral resection 60 platinum refractory 60 Erythropoietic therapies may 60 CVD mortality 60 antiangiogenic therapy 60 gastrointestinal stromal tumor GIST 60 TNF blocker therapy 60 EGFR gene 60 nonmelanoma 60 activating mutations 60 atrophic gastritis 60 gastric atrophy 60 mg kg dose 60 clusterin 60 lymph node 60 breast cancer subtypes 60 chemoradiation therapy 60 liver histology 60 biopsy Gleason 60 ara C 60 molecular subtypes 60 ovarian endometrial 60 familial ALS 60 ovarian pancreatic 60 variceal bleeding 60 neutropaenia 60 prostatic adenocarcinoma 60 demonstrated antitumor activity 60 thrombotic complications 60 breast endometrial 60 BRAF mutation 60 lymphoma subtypes 60 colorectal gastric 60 extranodal 60 sentinel lymph nodes 60 moderately emetogenic 60 SLN biopsy 60 acute myeloid 60 #F FDG PET 60 grade glioma 60 FGFR2 gene 60 PNH patients 60 resected 60 immunoreactivity 60 histopathologic diagnosis 60 familial pancreatic cancer 60 lymphomas 60 Waldenstrom macroglobulinemia 60 recurrent DVT 60 adjuvant radiation 60 CD# expression [001] 60 postoperative radiotherapy 60 CDKN2A 60 Multivariate analysis 60 ependymoma 60 Acute myeloid leukemia 60 colorectal carcinomas 60 KRAS status 60 premalignant lesions 60 achieved ACR# 60 recurrent ischemia 60 endoscopic remission 60 serum HCV RNA 60 myocardial ischemia 60 5-FU/LV 60 prostate breast 60 normal karyotype 60 paclitaxel cisplatin 60 Subgroup analyzes 60 TNF α 60 cisplatin gemcitabine 60 bleomycin 60 #p# [001] 59 aplastic anemia AA 59 WT1 59 plus gemcitabine 59 hematologic disorders 59 sonographic findings 59 kidney allograft 59 VEGF expression 59 transitional cell carcinoma 59 TMPRSS2 ERG fusion 59 tumor lysis syndrome 59 cranial irradiation 59 mycophenolate mofetil 59 endosonography 59 troponins 59 neuroendocrine carcinoma 59 microvascular complications 59 liver fibrosis 59 mycosis fungoides 59 thyrotropin 59 MYCN amplification 59 testicular germ cell 59 Adjuvant therapy 59 grade gliomas 59 liver resection 59 confidence interval CI 59 nonischemic 59 gene amplification 59 TT genotype 59 cGy 59 spinal cord compression 59 morphologic 59 urothelial bladder cancer 59 adjuvant cisplatin 59 gastrointestinal stromal tumor 59 Cholangiocarcinoma 59 myelofibrosis polycythemia vera 59 HER2 positive tumors 59 EGFR expressing 59 gefitinib 59 cytopenias 59 nutlin 3a 59 #q# [001] 59 remission CR 59 Upregulation 59 colorectum 59 neointimal 59 recurrent glioblastoma multiforme GBM 59 fallopian tube cancers 59 XELOX 59 μmol L 59 non squamous 59 Hepatocellular Carcinoma HCC 59 perioperative mortality 59 autonomic dysfunction 59 thyroid carcinomas 59 free survival PFS 59 oesophageal adenocarcinoma 59 upper gastrointestinal bleeding 59 symptomatic VTE 59 unknown etiology 59 TRAIL induced apoptosis 59 latent celiac disease 59 variceal hemorrhage 59 #q#.# [001] 59 XIENCE V PROMUS Stent 59 pilocytic astrocytomas 59 ductal 59 fluoropyrimidine 59 neurodevelopmental impairment 59 MSH2 59 malignant fibrous histiocytoma 59 CHD CVD 59 pre malignant lesions 59 salpingo oophorectomy 59 genetic polymorphisms 59 intrahepatic 59 supratentorial 59 EGFR TKI 59 Surgical resection 59 Stage IIIb 59 leucopenia 59 fibrosis 59 medullary thyroid cancer 59 STRIDE PD 59 ximelagatran 59 gemcitabine Gemzar 59 FLT3 ITD 59 leukemia ALL 59 hypercalcemia 59 NAT2 59 Sezary syndrome 59 locoregional disease 59 obstructive coronary 59 Glioblastoma Multiforme 59 PCNSL 59 pleural fluid 59 surgical debulking 59 complete cytogenetic 59 radioiodine therapy 59 % CI #.#-#.# [001] 59 autologous transplants 59 thromboembolic 59 pg ml 59 aberrant activation 59 RECIST 59 chemosensitivity 59 TNF antagonist 59 Helicobacter pylori infection 59 overt nephropathy 59 PAOD 59 carcinoma HCC 59 lung nodule 59 Immunohistochemical analysis 59 hepatoma 59 predictive biomarker 59 reintervention 59 missense mutations 59 hypervascular 59 Amrubicin 59 Flu Cy 59 renal pelvis 59 tumor xenograft models 59 CsA 59 COX2 59 KRAS mutation status 59 EpCAM expression 59 thyrotropin levels 59 concurrent chemoradiation 59 cardiotoxicity 59 squamous intraepithelial lesions 59 MGd 59 proteinuria 59 ependymomas 59 pneumonectomy 59 atheroma volume 59 subclinical hypothyroidism 59 mutational status 59 sustained virological response 59 SCr 59 cervical lymph node 59 metastatic NSCLC 59 intima media thickness 59 LRP5 59 Sjögren syndrome 59 ALT elevation 59 nonfatal stroke 59 Lung transplantation 59 diagnostic biomarker 59 myeloperoxidase 59 polypoid 59 adriamycin 59 occult metastases 59 appendiceal 59 Sentinel node biopsy 59 macrovascular events 59 undetectable HBV DNA 59 nonalcoholic steatohepatitis NASH 59 eribulin mesylate 59 germline mutations 59 scintigraphic 59 binary restenosis 59 pathologic 59 nonalcoholic steatohepatitis 59 androgen ablation 59 Raf MEK ERK 59 galiximab 59 tamoxifen Nolvadex ® 59 RECIST criteria 59 cell acute lymphoblastic 59 Rectal cancer 59 complement inhibitor eculizumab 59 liver decompensation 59 multivariate adjustment 59 bronchopulmonary dysplasia 59 fibrosis cirrhosis 59 gastric cardia 59 AML MDS 59 whose tumors overexpress 59 lymphangiogenesis 59 Lymphocytic 59 carboplatin paclitaxel 59 Renal Cell Carcinoma RCC 59 GNAQ 59 ASCUS 59 meningiomas 59 cyclophosphamide methotrexate 59 pancreatic colon 59 mTOR inhibitors 59 angiographically 59 microalbuminuria 59 tHcy 59 dysplastic lesions 59 resistant hormone refractory 59 HER2 gene 59 antibody titer 59 lymphoid 59 intraepithelial neoplasia 59 MetS 59 tumors 59 trastuzumab 59 portal vein thrombosis 59 timepoints 59 R0 resection 59 ZACTIMA 59 nonproliferative 59 standard chemotherapy regimen 59 lowest tertile 59 #p#.# [002] 59 seropositivity 59 Menopausal hormone therapy 59 grade serous ovarian 59 intra abdominal abscess 59 ventricular dysfunction 59 APOE e4 59 cell carcinoma 59 Bezielle 59 myocardial infarction MI 59 sporadic ALS 59 ultrasonographic 59 EGFR tyrosine kinase inhibitors 59 thyroid cancers 59 colorectal pancreatic 59 BEXXAR Therapeutic Regimen 59 biopsied breast 59 oral clodronate 59 intact parathyroid hormone 59 breast cancer metastasis 59 hemorrhagic complications 59 E#F# 59 thyrotoxicosis 59 isoenzyme 59 tracer uptake 59 tumor regression 59 epirubicin 59 parkinsonism 59 glomerular filtration 59 serum urate levels 59 Stage IIB 59 taxane chemotherapy 59 IPAH 59 endothelial activation 58 susceptibility loci 58 papillary RCC 58 SCCHN 58 BRCA2 gene mutation 58 vasculopathy 58 metastatic bone 58 HER2 amplified 58 leukemia APL 58 cryptogenic 58 FDG PET imaging